The Federal Trade Commission and the Department of Health and Human Services will investigate the causes of generic drug shortages and the role of middlemen in the supply chain.
The inquiry is focused on group purchasing organizations and drug distributors that may have pressured pricing and manufacturing, leading to drug shortages.